Par Drugs Valuation
| PAR Stock | 189.99 2.00 1.04% |
At this time, the company appears to be overvalued. Par Drugs And holds a recent Real Value of USD182.39 per share. The prevailing price of the company is USD189.99. Our model determines the value of Par Drugs And from analyzing the company fundamentals such as Price To Sales of 2.26 X, return on equity of 0.21, and Operating Margin of 0.30 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Par Drugs' price fluctuation is very steady at this time. Calculation of the real value of Par Drugs And is based on 3 months time horizon. Increasing Par Drugs' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Par stock is determined by what a typical buyer is willing to pay for full or partial control of Par Drugs And. Since Par Drugs is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Par Stock. However, Par Drugs' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 189.99 | Real 182.39 | Hype 189.99 | Naive 193.15 |
The real value of Par Stock, also known as its intrinsic value, is the underlying worth of Par Drugs And Company, which is reflected in its stock price. It is based on Par Drugs' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Par Drugs' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Par Drugs And helps investors to forecast how Par stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Par Drugs more accurately as focusing exclusively on Par Drugs' fundamentals will not take into account other important factors: Par Drugs Total Value Analysis
Par Drugs And is at this time forecasted to have takeover price of 2.19 B with market capitalization of 2.36 B, debt of 159.79 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Par Drugs fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.19 B | 2.36 B | 159.79 M |
Par Drugs Investor Information
The book value of the company was at this time reported as 78.69. The company recorded earning per share (EPS) of 14.84. Par Drugs And last dividend was issued on the 22nd of November 2021. The entity had 2:1 split on the 27th of April 2021. Based on the key indicators related to Par Drugs' liquidity, profitability, solvency, and operating efficiency, Par Drugs And is not in a good financial situation at the moment. It has a very high risk of going through financial straits in March.Par Drugs Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Par Drugs has an asset utilization ratio of 94.12 percent. This indicates that the Company is making USD0.94 for each dollar of assets. An increasing asset utilization means that Par Drugs And is more efficient with each dollar of assets it utilizes for everyday operations.Par Drugs Profitability Analysis
The company reported the revenue of 956.4 M. Net Income was 145.01 M with profit before overhead, payroll, taxes, and interest of 685.63 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Par Drugs' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Par Drugs and how it compares across the competition.
About Par Drugs Valuation
The stock valuation mechanism determines Par Drugs' current worth on a weekly basis. Our valuation model uses a comparative analysis of Par Drugs. We calculate exposure to Par Drugs's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Par Drugs's related companies.Complementary Tools for Par Stock analysis
When running Par Drugs' price analysis, check to measure Par Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Par Drugs is operating at the current time. Most of Par Drugs' value examination focuses on studying past and present price action to predict the probability of Par Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Par Drugs' price. Additionally, you may evaluate how the addition of Par Drugs to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |